Supplementary Online Content

Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial. *JAMA Oncol.* Published online January 24, 2019.
doi:10.1001/jamaoncol.2018.6258

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Sites of Enrollment

Site PI	Site Name	Patients
Taylor, Matthew	Knight Cancer Institute–Oregon Health & Science University, Portland, OR, USA	8
Kelly, Karen	University of California–Davis Comprehensive Cancer Center, Sacramento, CA, USA	7
Beck, Joseph	Highlands Oncology Group, Fayetteville, AR, USA	6
Disis, Mary	University of Washington School of Medicine, Seattle, WA, USA	6
Gordon, Michael	HonorHealth Research Institute, Scottsdale, AZ, USA	6
Aljumaily, Raid	Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK, USA	5
Gulley, James	National Cancer Institute, Bethesda, MD, USA	5
Lee, Wes	St Joseph Heritage Healthcare, Santa Rosa, CA, USA	5
Patel, Manish	Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA	5
Chaves, Jorge	Northwest Medical Specialties, Tacoma, WA, USA	4
Lockhart, Albert	Washington University School of Medicine, St. Louis, MO, USA	4
Mita, Alain	Cedars Sinai Medical Center, Los Angeles, CA, USA	4
Ellerton, John	Southern Nevada Cancer Research Foundation, Las Vegas, NV, USA	3
Hays, John	Ohio State University–James Comprehensive Cancer Center, Columbus, OH, USA	3
Iannotti, Nicholas	Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, FL, USA	3
Infante, Jeffrey	SCRI–Tennessee Oncology, Nashville, TN, USA	3
Verschraegen, Claire	University of Vermont Medical Center, Burlington, VT, USA	3
Wang, Ding	Henry Ford Hospital, Detroit, MI, USA	3
Weiss, Glen	Cancer Treatment Centers of America, Goodyear, AZ, USA	3
Babiker, Hani	Scottsdale Healthcare Corporation, Scottsdale, AZ, USA	2
Chandler, Jason	West Cancer Center, Memphis, TN, USA.	2
Dirix, Luc	Sint Augustinus-University of Antwerp, Antwerp, Belgium	2
Emens, Leisha	The John Hopkins University School of Medicine, Baltimore, MD, USA	2
Gurtler, Jayne	Metairie Oncologist, Metairie, LA, USA	2
Jerusalem, Guy	CHU Sart Tilman, Liege, Belgium	2
Kochuparambil, Samith	Virginia Piper Cancer Institute, Minneapolis, MN, USA	2
Malcolm, Albert	Signal Point Clinical Research Center, Middletown, OH, USA	2
Neidhart, Jeffrey	San Juan Oncology Associates, Farmington, NM, USA	2
Nikolinakos, Petros	Northeast Georgia Cancer Care, Athens, GA, USA.	2
Peguero, Julio	Oncology Consultants, Houston, TX, USA	2
Vaishampayan, Ulka	Karmanos Cancer Institute, Detroit, MI, USA	2
Arkenau, Hendrik-Tobias	Sarah Cannon Research Institute, London, UK	1
Boccia, Ralph	Regional Cancer Care Associates, Bethesda, MD, USA	1
Dowlati, Afshin	University Hospitals Case Medical Center, Cleveland, OH, USA	1
Eder, Joseph	Yale Cancer Center, New Haven, CT, USA	1
Frank, Richard	Whittingham Cancer Center, Norwalk, CT, USA	1
Hamid, Omid	The Angeles Clinic and Research Institute, Los Angeles, CA, USA	1
Khleif, Samir	Georgia Cancer Center–Augusta University, Augusta, GA, USA	1
McCune, Steven	Northwest Georgia Oncology Centers, Marietta, GA, USA	1

Mehnert, Janice	Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA	1
Nemunaitis, John	Mary Crowley Cancer Research Centers, Dallas, TX, USA	1
Powderly, John	Carolina BioOncology Institute, Huntersville, NC, USA	1
Robles, Robert	Bay Area Cancer Research Group, Pleasant Hill, CA, USA	1
Somer, Robert	Cooper Hospital University Medical Center, Camden, NJ, USA	1
Villa, Luis	AMPM Research Clinic, Miami Gardens, FL, USA	1
Wong, Deborah	University of California at Los Angeles, Los Angeles, CA, USA	1

eTable 2. Clinical Activity Based on PD-L1 Status in Evaluable Patients (N=114)

PD-L1 Cutoff	**PD-L1+**	**PD-L1–**	***P* Value**	**Hazard Ratio**
≥1% in tumor cells				
No. of patients	76	38		
ORR (95% CI), %	11.8 (5.6-21.3)	7.9 (1.7-21.4)	.748	
Median PFS (95% CI), mo 12-month rate (95% CI), %	2.7 (1.5-3.0) 8.8 (3.5-17.1)	1.4 (1.3-2.7) 10.9 (3.1-24.4)		0.764
Median OS (95% CI), mo 12-month rate (95% CI), %	13.8 (9.6-16.1) 53.1 (41.0-63.9)	7.0 (5.8-18.7) 36.6 (20.6-52.9)		0.880
≥5% in tumor cells				
No. of patients	32	82		
ORR (95% CI), %	12.5 (3.5-29.0)	9.8 (4.3-18.3)	.737	
Median PFS (95% CI), mo 12-month rate (95% CI), %	2.7 (1.4-4.0) 11.7 (3.4-25.8)	2.2 (1.4-2.7) 8.2 (3.2-16.2)		0.881
Median OS (95% CI), mo 12-month rate (95% CI), %	10.6 (7.1-20.6) 49.8 (30.9-66.2)	11.9 (7.5-16.1) 47.4 (35.7-58.1)		1.131
≥10% in tumor-associated immune cells				
No. of patients	16	98		
ORR (95% CI), %	0 (0-20.6)	12.2 (6.5-20.4)	.212	
Median PFS (95% CI), mo 12-month rate (95% CI), %	1.5 (1.3-5.4) 18.8 (4.6-40.2)	2.6 (1.4-2.8) 7.7 (3.2-14.6)		0.842
Median OS (95% CI), mo 12-month rate (95% CI), %	11.0 (7.6-16.1) 48.2 (20.8-71.2)	11.9 (7.0-16.1) 48.0 (37.4-57.8)		0.959

ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival.

eFigure. Kaplan–Meier Estimates of (A) Progression-Free Survival and (B) Overall Survival (N=125)

A.



B.